Is CAR-NK The Natural Successor To CAR-Ts?
Executive Summary
There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.
You may also be interested in...
Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
The Next Mega-Blockbusters Are Already Approved
The success of a drug depends on investment and lifecycle management. Keytruda is the most valuable drug in the industry, while trendy GLP-1 agonists are a prominent drug class.